XUNFEIHEALTH (02506) 2026 interim report: Another perspective on profitability approaching a turning point, "the first stock of large medical models" is being revalued.

Recently, iFlytek Medical (02506) delivered a mid-year report that is significant enough to prompt the capital market to reassess it. According to the financial report, the revenue for the first half of 2026 reached 446 million yuan, a year-on-year increase of 49.4%; the gross profit was 236 million yuan, a year-on-year increase of 53.5%; the gross profit margin rose to 52.9%; and the net loss during this period narrowed significantly to 48.1 million yuan, a 41.5% reduction year-on-year. After the financial report was released, the company's stock price experienced an overall increase of more than 30% over three trading days; CMB International raised the company's 2026 revenue forecast by 7.6%, setting a target price of 99.58 HKD and maintaining a "Buy" rating. Several leading brokerage firms, including Guoshen and Northeast, also issued positive assessments, arguing that this excellent performance is not merely a short-term rebound in earnings, but rather a structural improvement in the companys business and commercial model. The most noteworthy aspect of this mid-year report is not just the revenue growth rate itself, but the companys key transition from a "medical AI project company" to a "medical AI platform company" with all three curves of revenue quality, business structure, and profitability paths showing a positive inflection point. The core signal of this transformation points to a more imaginative proposition: iFlytek Medical is about to achieve profitability. Accounting Breakdown: Losses are Shrinking, Business is Growing The first key to understanding iFlytek Medicals mid-year report is distinguishing between "accounting losses" and the "essence of the business." The net loss of 59.3 million yuan does not correspond to operational blood loss but rather reflects strategic investments during the transformation period. During the same period, the gross profit of 236 million yuan represented a year-on-year increase of 53.5%, outpacing the revenue growth rate of 49.4%; the overall gross profit margin of approximately 52.9% has now firmly established itself in the threshold of AI software companies. Whats even more noteworthy is the significant improvement in the gross profit margin of the AI digital foundation business indicating that the maturity of foundational capabilities is reducing marginal service costs. Seeing the growth rate in historical context reveals its true significance: the revenue growth rate jumped from 24.7% for the entire year of 2025, and approximately 30% in the first half of 2025, to nearly 50%. The rate of loss reduction is more indicative than the absolute value itself. In the first half of 2026, the net loss attributable to the parent narrowed to 59.3 million yuan, marking a year-on-year reduction of approximately 20%. Coupled with the fact that the second half of the year is traditionally the peak revenue period for the medical IT industry, the path to profitability is now clearly visible. But this is not the key point. The most critical aspect is the qualitative change in commercial logic behind the narrowing losses. Transformation of Business Model: From "Building One-Time Projects" to "Ongoing Operational Fees" The opening of the profitability window is not an isolated event, but rather the result of multiple factors catalyzing together, including foundational technology, business structure, policy benefits, and a commercial closed loop. The company has focused its business on three segments: AI diagnostic assistants, AI health assistants, and AI digital foundations. This is not an accounting adjustment, but a clear signal to the capital market: the valuation logic is shifting from "medical IT integrator" to "AI product company." As of June 30, 2026, AI diagnostic assistants generated core revenue of 202 million yuan, an increase of 47.5% year-on-year. With the product deeply embedded into physicians workflows, evolving from a tool to an Agent, case generation, quality control, and clinical decision support are now deeply integrated into hospital operations, likely forming a software commercial closed loop characterized by "high-frequency usage continuous payment high replacement cost." During the same period, AI health assistants generated revenue of 182 million yuan, a remarkable increase of 74.9%, becoming the strongest growth engine. This growth was driven by in-depth efforts with existing customers, improved average transaction value, and expanded renewals, indicating that the product has entered a stage of releasing lifecycle value rather than relying solely on new points of expansion. The AI digital foundation serves as a foundational role for the G-end, supplying data and capabilities for both B and C sides, completing the G-B-C business closed loop. The two core engines of ARR supporting the profitability inflection point have established replicable business models, which management emphasized repeatedly during the performance briefing. The first is the imaging cloud business endorsed by medical insurance. Leveraging a mature model from Anhui, it is being replicated in Guangxi and gradually expanding to other provinces. The AI quality control capabilities outperform human experts, enabling cross-hospital image retrieval in three seconds, effectively addressing the pain point of repetitive examinations and saving medical insurance funds. According to plans, the goal is to charge patients for services exceeding 100 million visits by the end of the year, striving to reach 300 million visits by 2028, with potential expansions into pathology and test-related imaging services, thereby creating a stable and continuous operating revenue stream. The second is the AI post-diagnostic patient management service, which is a highly flexible innovative business that patients pay for voluntarily. Clinical data shows this service reduces the unplanned readmission rate from 1.9% to 0.9% and increases medication compliance from 49% to 95%. In the future, it will be replicated en masse across leading top-tier hospitals nationally, creating a high-margin incremental revenue source. These two models rely on both medical insurance funding and personal payments, with clear cash flow sources and continuously declining marginal costs, which are crucial for driving non-linear profit releases. Strategic Restructuring: From "Burning Cash to Build Capabilities" to "Collecting Rent and Operating Models" If in the past few years iFlytek Medical was focused on "burning cash to build capabilities" developing foundational models, establishing grassroots networks, and refining benchmark scenarios then the mid-year report for 2026 signifies the commencement of the "collecting rent and operating modes" phase. Management revealed critical information during the performance meeting: the AI diagnostic assistant has evolved beyond a simple CDSS upgrade; it has transformed into an Agent shifting from "the doctor asking AI a question" to "AI participating in the entire workflow of the doctor." This reflects a shift in the commercial aspect, moving away from one-time project purchases towards a continuous fee model based on usage and subscriptions. The data flywheel is already in motion. The system currently handles over 1.71 million diagnostic assists and 520,000 patient feedback entries daily, with real-world data continuously informing iterative model improvements. The accuracy rate of diagnostic treatment recommendations has reached 92%, with partnerships established with 60 of the top 100 hospitals nationwide and eight of the top ten hospitals collaborating. These are not plans on a PowerPoint presentation, but real data that has already been operationalized. Of course, beyond the technology, the growth story extends beyond domestic boundaries. In June 2026, iFlytek Medical signed a strategic cooperation memorandum for AI healthcare with the Golden Agri-Resources Group in Indonesia, marking the companys first major overseas market, with the ability to export a complete set of AI healthcare solutions verified, laying the groundwork for opening a second growth curve in the long term. Meanwhile, Huawei and iFlytek Co., Ltd. are jointly participating in the construction of national-level AI infrastructure in Brazil, indicating that Chinese AI companies are transitioning from single product exports to co-building national-level computational power and large model ecosystems. This project not only showcases the comprehensive strength of the iFlytek system in computational engineering and multilingual pre-training but also solidifies the technical foundation for the vertical capabilities of iFlytek Medical, with Brazil and other emerging Latin American markets poised to become the next destination for replicating and elevating overseas expansion after Southeast Asia. Valuation Shift: Reanchoring from PS to PE Coordinates The market continues to price iFlytek Medical within the framework of "AI medical loss stocks," employing PS valuation. However, if it achieves profitability in 2026, the valuation method must switch to PE. The impact of this shift lies in the fact that before profitability, the market only focused on revenue growth; after profitability, every marginal percentage point increase in profit margin will be amplified by the PE. With a revenue growth rate of 49.4% and a gross profit margin of 52.9% as the foundation, once it crosses the breakeven point, each percentage point increase in profit margin from 0% to 10% corresponds to a market valuation increase worth billions. On a deeper level, on July 15th, the National Health Commission held a nationwide on-site meeting in Hefei, clearly stating its goal to achieve comprehensive coverage of intelligent auxiliary applications in grassroots diagnosis and treatment by 2030. The iFlytek Medical Intelligent Assistant already covers over 800 counties and holds over 80% market share, with the promotion to the remaining 2,000 counties backed by strong policy enforcement and guaranteed financial support. This is not a tentative growth projection but a certainty with a clear timeline and funding sources. Once XunfeiHealth achieves profitability, it will mark a milestone in the Hong Kong stock market's medical AI sector the complete loop from "technical leadership" to "commercialization" and finally to "profit verification" will be realized. A clean, operationalized medical AI platform company is the ideal vessel to capture the long-term growth potential in this field. Management's closing remark at the performance meeting may serve as the best footnote: "Our goal is not only to stand by our technological strength but also to win investor recognition through mature business logic and verifiable financial performance." This path has already begun to take shape over the past six months.